Clear Search

Showing 2 results for “Rovin B” published 2025.

July 2025

Effect of long-term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies

Arthritis & Rheumatology 2025; 0:1–7 doi: 10.1002/art.43209

Exposure to voclosporin for a median of 18 months was not associated with onset or progression of nephrotoxicity based on evaluation of histologic compartments and vascular lesions. Rovin et al. characterised the impact of voclosporin on kidney histology in patients with LN who had protocolized repeat kidney biopsies in the AURORA clinical trials.

more…

February 2025

Efficacy and safety of obinutuzumab in active lupus nephritis

NEJM, 2025. Epub ahead of print. DOI: 10.1056/NEJMoa2410965

Furie et al. demonstrated that obinutuzumab plus standard therapy significantly improved complete renal response at Wk76 compared with placebo. No unexpected safety signals were identified, though infections and COVID-19-related events were more frequent in the obinutuzumab group.

more…